A recent analysis published in Obstetrics & Gynecology considers screening for hepatitis B antibodies and vaccinating pregnant women without immunity to be a cost-effective health measure.
Although vaccination is not routine during pregnancy, guidelines from the American College of Obstetricians and Gynecologists recommend screening and vaccinating at-risk women for hepatitis B during pregnancy.
In their recent study, Dr. Prabhu and her colleagues determined how universal hepatitis B surface antibody screening and vaccination for hepatitis B affected factors like cost, cost-effectiveness, and outcomes. They included hepatitis B virus cases and long-term problems associated with hepatitis B infection, like hepatocellular carcinoma, decompensated cirrhosis, liver transplant, and death.
They found the universal screening and vaccination program cost-effective, with fewer cases of hepatitis B, deaths, decompensated cirrhosis cases, and liver transplants in their model. They also found an incremental cost-effectiveness ratio of $1,890 per quality-adjusted life-years (QALYs) and the total increased lifetime cohort cost as $13,841,889. This model holds true even in scenarios with a high level of hepatitis B immunity and no presence of at-risk women in the model.
If real-world studies show that a hepatitis B universal screening and vaccination program is cost-effective, guidelines must reconsider the population to be screened and vaccinated.
Under guidelines that direct all pregnant women to be screened and vaccinated for hepatitis B regardless of risk, conducting one extra blood test, among many other blood tests at the first prenatal visit, is no harm.
Thus, Clinicians must consider adding hepatitis B screening to prenatal care, given that ACOG recently released routine hepatitis C screening for pregnant women as a practice advisory.
Craven J. Universal hepatitis B screening, vaccination deemed cost-effective for pregnant women. MDEdge. February 10, 2022. https://www.mdedge.com/obgyn/article/251664/preventive-care/universal-hepatitis-b-screening-vaccination-deemed-cost?reg=1
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details